The Power of an Evolving Pitch

3 Nov

By Karen Deyo, Director of Investor Research, Israel BD, LSN

The RESI conference schedule is based on the reality that startups need to connect with investors multiple times over the course of a year to build and maintain relationships to close fundraising deals. The power of RESI is not just in the chance to meet with an ever-rotating list of new and familiar faces, but also to gauge the traction of your pitch as your company grows and develops.

A company’s pitch is always evolving – as you advance and achieve milestones, necessary pivots, and strategy changes based on your product development, you hone your story. As your story shifts, you start the process anew to find what message resonates the most with your investor audience. As frustrating as it may seem, attending frequent events and taking as many meetings as possible is a necessary step to gaining valuable feedback, as well as allowing you to close your deals.

Digital RESI, November 15-16, is focused entirely on virtual partnering – register today to request meetings with these investors  to make connections. RESI JPM is just around the corner, Life Science Nation (LSN)’s biggest event of the year – don’t miss out on your chance to hone your pitch before then!

Register-now-button-new

RESI-Nov-2022-Banner-500H-11032022
RESI-SF-2023-Banner-1100px-11032022

Hot Investor Mandate: Major Conglomerate Affiliated I-Bank Invests in Privately Owned and Publicly Traded Companies Across All Life Science Sectors Globally

3 Nov

A premier investment bank affiliated with a major conglomerate has an investment arm that invests across public, private, and mezzanine asset classes across various industries, including life sciences and healthcare. The firm is stage agnostic, but has invested in pre-Series A and Series A rounds and has an increased interest in early-stage technologies. Investments can be made out of the firms’ proprietary capital or through special purpose vehicles (SPVs). The firm is interested in global opportunities.

The firm is interested in all healthcare verticals: therapeutics, life science tools and diagnostics, medical devices, and digital health.  Within therapeutics, the firm is open to all types of modalities, indications, and therapeutic classes. The firm is stage agnostic and has invested in all rounds from pre-A to crossover rounds.

The firm has no specific company or management requirements. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western-Europe Based VC Firm Invests Up to €8M in Seed to Series A Round Companies, Including Pre-Clinical Therapeutics, Devices, Digital Health, and More

3 Nov

A firm based in Western Europe invests in early stage companies in the life sciences and Information Technology Sectors. The firm also invests in public companies through Convertible Bonds and secondary alternative markets. The firm also offers Venture Debt financing for private companies. Within Life Sciences, the firm invests in rounds of EUR 2-8 Million Seed and Series A rounds. The firm invests in Europe and North America.

In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. Outside of Therapeutics, the firm invests in companies that are revenue positive. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, The firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 8 million to reach a human Proof of Efficacy. In Spain, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. In North America, The firm seeks to co-invest in rounds led by top-tier Venture Capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Fund Allocates $1-5M in Early Stage Companies With USA Focus, Most Interested in Therapeutics and Diagnostics Sectors

3 Nov

A venture capital firm founded in 2016 and is headquartered in the USA is currently on their second fund, and the typical check size is flexible, with a typical first check for coming at the seed through series A stage between $1M-5M. The firm is open to both leading or following the investments, but prefers to lead at the seed stage.  The firm focuses on companies located in the US.

The firm is looking for new investment opportunities in sectors focused on applied biology and chemistry, including the therapeutics and diagnostics sectors as well as sustainability, synthetic biology, agtech, and other industrial sectors. The firm is opportunistic in terms of sub-sectors and indications, including all phases of development for therapeutics and various use-cases of synthetic biology. The firm is not typically interested in healthcare services or healthcare IT.

The firm invests in companies in the US and likes to see second or third time entrepreneurs, however the firm will back bold first time entrepreneurs with compelling technologies. The firm is open to both leading or following the investment, and could seek a board seat in certain deals.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Life Sciences Research Tools Manufacturer Strategically Invests and Partners With Companies that Fit Their Existing Product Portfolio

3 Nov

A life science research tools manufacturer based in Western Europe with offices worldwide is interested in partnering with companies developing cutting-edge products that are a strategic fit for the firm’s portfolio. The firm is looking for novel product line addition opportunities globally and possible investments in early stage companies located in North America or Europe who are pursuing technology-leading approaches in the firm’s selected application fields.

The firm is focused on investing in companies that are developing products used in research labs, including consumables, bioprocess and lab automation equipment, and digital tools used by research scientists. The firm generally invests in companies with products that are at the commercial stage. The firm is targeting emerging, non-public companies who are pursuing applications in the areas of Molecular Biology, AI/Digital and Cell Biology.

The firm is flexible about partnering structure and open to a range of approaches including licensing, co-development, equity investments and acquisitions. The firm is a first-for-the-company, corporate venture fund with a charter towards select, new business line-directed equity investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Bundle Extended to Tomorrow

27 Oct

By Caitlin Dolegowski, Marketing Specialist, LSN

The end of the year is a critical time for early-stage fundraising. It is imperative for founders to end the year on a strong note and be ready to continue connections and building new relationships into the new year. To aid in this endeavor, Life Science Nation (LSN) is offering an extended bundle for Digital RESI, November 15-16 and RESI JPM San Francisco, January 10-12.

Digital RESI is LSN’s virtual event, featuring two days of dedicated partnering. This event provides early-stage entrepreneurs with the opportunity to connect with capital and licensing partners who are a fit for their product and stage of development before the end of the year. If Digital RESI November is a dress rehearsal, then consider RESI JPM San Francisco opening night. RESI JPM San Francisco is a hybrid event taking place during the JPM healthcare week – the life science industry’s biggest event of the year. The hybrid format features a day of in-person partnering, live investor panels, educational workshops, and the Innovator’s Pitch Challenge (applications now open!) on January 10, followed by two days of dedicated virtual partnering to allow attendees to take advantage of the RESI platform while also experiencing all the events taking place simultaneously.

The bundle package extended deadline is tomorrow, October 28. Sign up to take advantage of these deals and save $1,000 to ensure a strong end to the 2022 fundraising season and a promising start to the next one.

Register-now-button-new

RESI-Nov-2022-500-H-with-border

RESI-SF-2023-Banner

Voices of the 2022 Innovator’s Pitch Challenge

27 Oct

By Rory McCann, Director of Marketing & Conference Producer, LSN

Applications are now open for the first 2023 Innovator’s Pitch Challenge (IPC) taking place in-person at RESI JPM San Francisco on January 10! The IPC is Life Science Nation (LSN)’s pitch competition dedicated to putting talented founders and promising tech in front of a live panel of investors who are a fit for their product and stage of development. The IPC is a popular mainstay at both digital and hybrid RESI events, and RESI JPM San Francisco will be no exception!

Learn more about the IPC and hear from 2022 winners. The following interviews were with companies and founders who have found value in the process and connections associated with their pitch experience with RESI. Applications close November 30, so submit your application today!

RESI_JPM_IPC_Banner

RESI-Nov-2022-500-H-with-border

RESI-SF-2023-Banner

← Older Entries
Newer Entries →